
up ep estim follow
co result remain sidelin share
await detail new ceo uwe rohrhoff strateg review overal
result better forecast ep vs estimate
driven stronger revenu consum unit chc america
yoy chc intern yoy
higher profit margin case segment see
increas oper margin well chc america chc
rx segment remain profit segment
co net sale impact suppli disrupt
scopolamin patch product relaunch
manag re-affirmed revenu guidanc ep
 new product expect gener
revenu gener proair launch expect
co surpass estim report adj ep
beat forecast report revenu vs
estimate better expect oper margin
vs estimate higher gross margin vs
reiter net sale target adj oper
incom adj ep within net
sale co lower rx pharma estimate increas
chci estimate expect rx pharma adj oper
margin declin yoy
co gener oper cash help fund
repurchas share cost
valuat maintain neutral rate share
dont assign pt neutral-r stock dcf analysi suggest
share worth per share
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
prgo revenu exceed estimate segment consum healthcar america consum healthcar
rx pharma sale weaker expect
rx pharma report yoy declin
co surpass estim report adj ep beat forecast report
revenu vs estimate better expect oper margin vs
estimate higher gross margin vs estimate
reiter net sale target adj oper incom adj ep
within net sale co lower rx pharma estimate increas chci estimate
expect rx pharma adj oper margin declin yoy
perrigo compani plc incom statement financi project sell averag basic averag dilut analysisyoy sale dilut ep compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
